October 7th, 2014
Another Reason for Open Access to Clinical Trial Data?
Harlan M. Krumholz, MD, SM
A correction to the RE-LY trial results, partly brought to light because of litigation, has Harlan Krumholz wondering if this is another example of why we should have open access to clinical trial data.
October 6th, 2014
Selections from Richard Lehman’s Literature Review: October 6th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include medical device safety and effectiveness, familial hypercholesterolemia, and more.
October 6th, 2014
Nissen Urges Prompt Revision of Cardiovascular Guidelines
Larry Husten, PHD
Sparked by a new study that once again finds serious flaws in the cardiovascular risk calculator at the heart of the American College of Cardiology/American Heart Association cardiovascular guidelines, Steve Nissen states that “the ACC and AHA should promptly revise the guidelines to address the criticisms offered by independent authorities.” The CV risk calculator is a […]
October 1st, 2014
Case: Testosterone Replacement Therapy and CV Risk
Seth D Bilazarian, MD, Anna Catino, MD and James Fang, MD
A 47-year-old man presents to the hospital reporting 4 days of chest pain that occurs during treadmill exercise, left-arm and jaw discomfort, and shortness of breath with diaphoresis. His medical history is noteworthy only for orthopedic surgeries and use of testosterone replacement therapy for reportedly low testosterone syndrome. He does not smoke and drinks alcohol only […]